Submit Manuscript  

Article Details

PCSK9 inhibition could be effective for acute myocardial infarction


Baris Gencer* and François Mach  


In this review, we will explore the role of PCSK9 and inhibition of PCSK9 in patients after acute myocardial infarction (MI). Despite the implementation of evidence-based therapies to improve outcomes, mortality at one-year remains at 12-15% and the need to further reduce complications related to MI persists. Mechanistic and epidemiologic studies suggest that the naturally occurring PCSK9 protein increases coronary plaque vulnerability through several pathways, including pro-inflammatory LDL-C oxidation and direct modification of plaque composition. PCSK9 inhibitors are a class of drugs with proven efficacy in patients with recent MI. The latest guidelines recommend the use of PCSK9 in patients with recent MI early in the process of care to reduce LDL-C values and associated morbidity. The use of PCSK9 inhibition could be beneficial for mortality reduction after an acute MI and should be tested in an appropriately powered randomized controlled trial.


lipids, myocardial infarction, acute coronary syndromes, lipid-lowering, cardiovascular disease


Cardiology Division, Geneva University Hospitals, Cardiology Division, Geneva University Hospitals

Full Text Inquiry